PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$36.64 USD
+0.48 (1.33%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $36.64 0.00 (0.00%) 6:20 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
PTC Therapeutics, Inc. [PTCT]
Reports for Purchase
Showing records 61 - 80 ( 147 total )
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Translarna Tracking Well, But SMA Program Delayed, Lowering to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Impressive 1Q15 for Translarna Tarnished by SMA Setback; Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
1Q15 Preview- Focus is on Translarna Commercial Launch
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Drisapersen''s Regulatory Future Has Implications for PTC Therapeutics
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Smart Strategy Moves Translarna Launch at Faster Clip than We Expected; Increasing PT
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
ACT-DMD Phase-3, Defining Moment for Post Transcription Therapeutics
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Assuming Coverage with OUTPERFORM and $68 Price Target; Blazing a Trail
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
A Disease Modifying Therapy for SMA Is Up Next
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D